热门资讯> 正文
Ultragenyx将申请加速批准罕见代谢疾病候选药物
2024-06-13 04:40
- Ultragenyx (NASDAQ:RARE) said it would submit a Biologics License Application to the U.S. FDA seeking accelerated approval of UX111, a gene therapy for Sanfilippo syndrome, a rare metabolic disease.
- The company noted that following a recent meeting with the agency, it was agreed that cerebral spinal fluid heparan sulfate could be used as a surrogate endpoint.
- A pre-BLA meeting with the agency is still needed, but Ultragenyx is eying a filing late this year or in early 2025.
- UX111 would be given as a one-time treatment. Sanfilippo syndrome is a fatal lysosomal storage disease that mostly impacts the central nervous system. There are no approved therapies.
- Separately, after Wednesday's closing bell, the company said it has begun a public offering of up to $350M of common stock and pre-funded warrants, sending shares down ~3% in after-hours trading.
More on Ultragenyx Pharmaceutical
- Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
- Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
- Ultragenyx upped at Goldman Sachs on bone disorder treatment
- Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Ultragenyx Pharmaceutical
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
